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Introduction
Adult-onset Still’s disease (AOSD) is an 
uncommon systemic infl ammatory dis-
order of unknown etiology, character-
ized by high-spiking fever, evanescent 
salmon-pink rash, leukocytosis, hepatic 
dysfunction, polyserositis, lymphad-
enopathy, splenomegaly, arthritis or ar-
thralgias (1). Although its pathogenesis 
remains unclear, abnormalities in cy-
tokine serum levels documented a Th1 
predominance with high serum con-
centration of IL-1, IL-6, TNF-α, IFN-γ
and soluble IL-2 receptor, candidating 
AOSD as a Th1 mediated disease (2).
Several conventional treatments have 
been used in AOSD, such as non-ster-
oidal anti-infl ammatory drugs, often in 
combination with corticosteroids, and 
immunosuppressive therapy (metho-
trexate, azathioprine, cyclosporine A, 
lefl unomide, and cyclophosphamide) or 
intravenous gammaglobulins (3). More 
recently, anti-cytokine agents (anti-
TNF-α anti-IL1, anti-IL6) have been 
sporadically used in refractory AOSD, 
opening new avenues to the therapeutic 
approach of this disease, which, up to 
now, remains empirical. The IL-1 recep-
tor antagonist (IL-1Ra) anakinra seems 
to be effective for AOSD (4-12) even 
if neutralisation of IL-1 might be more 
effective in patients with highly active 
systemic disease than in patients with 
chronic arthritis, with no or less intense 
systemic symptoms (12) (Table I).
We report three cases of AOSD with 
severe joint involvement resistant to 
conventional treatment where anakinra 
administration resulted in sustained re-
mission. Moreover, the benefi t on arthri-
tits was confi rmed by musculoskeletal 
ultrasound (US).
Patients and methods 
Between 2000 and 2007, 18 patients 
with AOSD classifi ed according to 
Yamaguchi criteria were seen in the De-
partment of Rheumatology, Sapienza 
Università di Roma. 
Among them, 3 were considered refrac-
tory to traditional treatment and, after 
obtaining informed consent, were treat-
ed with anakinra (100mg/subcutaneous-
ly daily). The patients were evaluated at 
baseline and after 3 months of anakinra 
treatment for systemic symptoms (fever, 
exanthema, lymphadenopathy, hepat-
osplenomegaly, and serositis), tender 
joint count (TJC), swollen joint count 
(SJC), physician global assessment of 
disease activity, patient assessment of 
pain; DAS28 was calculated and ACR 
response considered (13). The follow-
ing laboratory values were also collect-
ed: haematological profi le, fi rst-hour 
erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP), and serum 
ferritin levels. Laboratory data and joint 
scores before treatment are summarized 
in Table II. 
US was performed in hand and wrist 
bilaterally in the patients 1, 2 and 3; 
in patient 1 knee joint was also stud-
ied. The joints evaluated were chosen 
because they were involved in our pa-
tients. US was performed by an expe-
rienced rheumatologist sonographer, 
using a Philips/HP Image Point HX 
machine equipped with 10 and 14 MHz 
linear probes for knee and wrist/hand 
respectively. Power Doppler (PD) was 
also applied with the following settings: 
frequency 7.5 MHz, PRF 700-1000Hz, 
gain 18-40dB, low fi lter. The joints were 
examined according to EULAR guide-
lines for ultrasonography in Rheuma-
tology and the presence of alterations 
within the joint and periarticular soft 
tissues were considered to be present 
according to OMERACT defi nitions 
for ultrasonographic pathology related 
to common pathological lesions seen 
in patients with infl ammatory arthritis 
(14, 15). The presence of infl ammation 
was documented in joints and/or peri-
articular tissues (joint effusion, syno-
vial proliferation, hyperaemia in the 
synovial tissue, tenosynovitis) together 
with the presence of permanent dam-
age (bone erosions and cartilaginous 
abnormalities). For all the changes a 
semiquantitative score (0-3) was used 
for each structure examined, where 0 
indicated the absence of any change 
and 1 to 3 the presence, respectively, 
of slight, moderate, and severe chang-
es. The subsequent summed total was 
used as an indicator of global change in 
each joint (single-joint score). The sum 
of the single-joint scores was used as 
an indicator of overall polyarticular in-
volvement in each patient (total score)
(16). 
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PD evaluation was performed for the 
analysis of vascularization of the syno-
vial membrane with a scoring system 
ranging from 0 to 3 (indicating respec-
tively absence of increased perfusion 
or minimal, moderate severe perfusion) 
(17). The single joint scores were added 
to obtain a global US score. 
Case 1
A 32-year-old north African woman 
presented with symmetric poliarthritis 
of wrists, hands and knees, intermittent 
fever (up to 39°C), faringodynia and 
rash associated to increase in C-reac-
tive protein (CRP) level (60mg/liter), 
ESR 38 mm/h and ferritin (1030 ng/
ml). After the exclusion of infective, 
neoplastic and other rheumatic disor-
ders, AOSD was diagnosed. The pa-
tients responded only partially to treat-
ment (methotrexate 15 mg/im weekly 
for fi ve months, hydroxychloroquine 
(HCQ) 400 mg/daily added to metho-
trexate (MTX) in the last 2 months, oral 
prednisone 25 mg/daily and indometa-
cine) and even if biological markers of 
activity ameliorated, an invalidating 
hand, wrist and knee arthritis persisted. 
US, perfomed in the involved joints, 
showed wrists synovial proliferation 
with erosions of radio-carpal bone sur-
face, tenosynovitis of left fl exor carpi 
radialis and fl exor carpi ulnaris, syno-
vitis of second and third MCP and knee 
joint effusion. MTX was stopped and 
Table I. Anakinra therapy in AOSD. Principal studies published so far.
Authors Patients Concomitant therapy Follow-up Patients evaluation
Rudinskaya A et al. (2003)4 1 pt PDN, MTX 12  months ESR, CRP, ferritin, WBC
Aelion J et al (2004)6 2 pt Pt 1: PDN, MTX Not specifi ed ESR, ferritin, WBC
  Pt 2. no therapy 
Haraoui B et al. (2004)7 3 Pt 1. PDN, Cy Pt 1: 6 months Only clinical response
  Pt 2: PDN, MTX, HCQ Pt 2: 4 months
  Pt 3: PDN, MTX Pt 3: 5 months 
Fitzgerald AA et al. (2005) 9 4 pt Pt 1: PDN Pt1*: 12 months Pt 1: ferritin, CRP, WBC, IL18
  Pt 2: PDN Pt 2**: 14 months  Pt 2: ESR, WBC
  Pt 3: PDN, MTX Pt 3: 6 months Pt 3: CPR, WBC, ferritin
  Pt 4: PDN Pt 4: 12 months Pt 4: CPR, WBC, ESR, ferritin
Vasques Godinho FM et al. (2005) 5 1 pt PDN, MTX 18 months ESR, WBC
Kalliolias GD et al. (2007) 10 4 pt PDN 5-17 months Clinical evaluation, WBC ESR, CRP, ferritin
Kötter I et al. (2007) 11 4 pt Pt 1: PDN, LFN 12 months Clinical evaluation, ESR, CRP, IL-6,
  Pt 2: PDN, MTX  TNF-α
  Pt 3: PDN, MTX
  Pt 4: PDN; MTX 
Lequerrè T et al. (2007) 12 15 pt 12 pts: PDN 1-27 months  ACR response, HAQ, clinical evaluation
  10 pts: MTX
  1 pt: MMF + col
  1 pt: col 
*On two different occasions the patients witheld anakinra with reactivation of the disease. She fi nally progressed to macrophage activation syndrome and 
cyclosporine was added. **On one occasion anakinra was stopped and successfully restarted.
(MTX: methotrexate; PDN: prednisone; Cy: cyclophosphamide; MMF: mycophenolate mofetil; LFN: lefl unomide; HCQ: hydroxychloroquine; col: colchi-
cine; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; WBC: white blood cell).
Table II. Laboratory parameters, joint clinical and sonographic scores before and after three months of treatment with anakinra.
 Patient 1 Patient 2 Patient 3
 Baseline After 12 weeks Baseline After 12 weeks Baseline After 12 weeks
ESR (mm/h) 18 4 8 9 68 8
CRP (mg/dl) 6 1 5 2 32 3
Ferritin (ng/ml) 1130 28.3 118 13.3 820 62.5
Tender joint 12 4 18 1 14 2
Swollen joint 10 1 8 0 6 0
Prednisone (mg/daily) 25 5 25 12.5*  25 7.5
VAS for activity disease of patient 76 20 64 5 72 10
VAS for activity disease of physician 78 46 58 5 70 5
DAS28 index 5.91 2.79 5.66 2.10 6.77 2.3
ACR response – ACR50 – ACR50 – ACR20
US score 18 4 48 12 22 6
*on alternate days.
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anakinra started with a progressive im-
provement of joint symptoms. By the 
end of the 8th week of treatment the pa-
tient developed a diffuse itching rash 
of the face, limbs and abdomen. Ana-
kinra was discontinued and MTX was 
reintroduced. US performed after ana-
kinra discontinuation showed improve-
ment of the synovitis in the second and 
third MCP, resolution of synovitis and 
tenosynovitis in the wrist and of joint 
effusion in the knee. The patient, treat-
ed with MTX 15 mg weekly and low 
doses of oral corticosteroids, was still 
in clinical remission 6 months after 
anakinra discontinuation. 
Case 2
A 32-year-old Caucasian women pre-
sented fever up to 39°C, evanescent 
macular rash, lymphadenopathy, ar-
thritis of hands and wrists, fatigue and 
myalgia. Laboratory evaluation showed 
a white blood cell (WBC) count of 
15,530/μl, ESR 120mm/h, CRP 47mg/
dl and ferritin 993ng/ml. Other neoplas-
tic, infl ammatory and infective diseases 
were excluded and AOSD diagnosed. 
She was initially treated with MTX 15 
mg im/weekly, HCQ 400 mg /daily, 
prednisone 25 mg with disappearance 
of fever, rash and lymphadenopathy, 
amelioration of laboratory infl amma-
tory markers but persistence of severe 
joint involvement. It was not possible to 
taper prednisone. At baseline US evalu-
ation of hand and wrist showed bilateral 
effusion in 2nd, 3 nd and 4 nd MCP and 
wrist joints with synovial proliferation 
and positive PD. Moreover, tenosynovi-
tis was present in fl exor tendons of 2nd, 
3nd and 4nd fi ngers. Anakinra was started 
and after three months, US performed 
in the same joints studied at baseline, 
demonstrated the resolution of teno-
synovitis of hand and wrist, with per-
sistence of mild effusion in 2nd and 3 nd
MCP and wrist joints bilaterally. Pred-
nisone could be was tapered up to 12.5 
mg on alternate days. 
Case 3
A Caucasian women with Turner’s 
disease (mosaicism 90%XX; 10%XO) 
periodically treated with intravenous 
immunoglobulins because of selec-
tive IgG1 defi ciency was diagnosed 
with AOSD (wrist and hand arthritis, 
remittent fever up to 39°C, maculo-
papular rash, increase of ESR, CRP, 
ferritin and transaminases) at the age 
of 16 and she was successfully treated 
with oral prednisone. At 22 years old, 
there were new episodes of fever and 
skin rash, hepatic involvement and se-
vere hand and wrist arthritis; this last 
feature was resistant to HCQ 400 mg/
daily and oral prednisone 25 mg/daily 
while other symptoms had subsided. 
US showed intrarticular effusion with 
synovial proliferation at the radio-car-
pal joints, mild intra-articular effusion 
at the MCPs; tenosynovitis of the 2nd 
and 4nd fi nger fl exor tendons. Anakinra 
100 mg fl  sc/daily was started with dra-
matic improvement; prednisone could 
be tapered to 7.5 mg daily. US per-
formed after three months in the same 
joints showed the presence of bilateral 
mild effusion in the radio-carpic joint 
and 2nd  and 3nd MCP joint.
Results
Table II shows laboratory parameters, 
joint clinical and sonographic scores be-
fore and after three months of treatment 
with anakinra. A relevant improvement 
of joint involvement was recorded in 
all the patients, in particular the mean 
DAS28 reduced from 6.1 to 2.2; when 
considering the ACR response criteria, 
2 patients achieved ACR50 response 
and one patient ACR20 response. US 
evaluation demonstrated a good re-
sponse to treatment: mean US score 
decrease from 29.3 to 6.6. (Fig. 1). The 
mean dose of steroids could be reduced 
in all the patients. 
Further follow-up
Two patients (cases 2 and 3) are cur-
rently treated with anakinra, with mean 
follow-up duration of 92 weeks. Patient 
2 is still in remission after 29 months 
without side effects; patient 3 was in 
Fig. 1. Longitudinal and transverse scan of superfi cialis and profundus fl exor tendon of the second fi nger before (A) and after therapy with anakinra in patient 
2. (A): hypoechoic region (*) around fl exor tendon as from tenosynovitis; (B): disappearance of hypoecoic region, as from resolution of tenosynovitis.
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remission up to 12 months of anakinra 
treatment, when presented a fl are-up of 
hand and wrist arthrits with improve-
ment after increase of steroid dosage. 
Discussion
Evidence-based medicine guidelines 
for the management of AOSD are lack-
ing and this disease still represents a 
therapeutic challenge.  Recent advances 
in AOSD pathogenesis advocate a key 
role for infl ammatory cytockines such 
as IL-1 and IL-18 in the disease patho-
genesis, favouring the usage of block-
ing agents against these molecules in 
refractory AOSD treatment (18-20).
IL-1 is a potent pyrogen and hemato-
poietic growth factor and it is known 
to up-regulate, through IL-6 synthesis, 
the expression of acute-phase reactants. 
Moreover IL-1 appears to mediate the 
disease also at articular level by inter-
acting with other cytockines such as 
IL-18 and TNF-α (21). All these data 
correlate with the biological effects 
observed in AOSD patient after anak-
inra administration, showing marked 
decrease in IL-1, IL-18, IL-6 levels, 
signifi cant clinical improvement with 
fever and leucocytosis disappearance 
(22-25). 
Reports of anakinra use in AOSD are 
limited. Rudinskaya et al. report the 
case of an adult patient with AOSD, 
previously refractory to conventional 
therapies, who dramatically responded 
to the addition of anakinra to MTX (4). 
Similar results were subsequently ob-
tained in other cases (5-9) even in the 
absence of the concomitant administra-
tion of MTX. IL-1 blockade seems to 
lead to a sustained remission and al-
lows the tapering if not complete ster-
oid withdrawal. 
Recently, Kalliolias described 4 pa-
tients who experienced a fast and safe 
response to anakinra, with a steroid 
sparing effect (10). Kötter confi rmed 
this result in 4 other patients, underly-
ing that IL-18 serum levels, CRP, ESR, 
liver enzymes, ferritin, and WBC, may 
be helpful in assessing disease activity 
and response to treatment (11). Lequer-
rè reported the results obtained in 20 pa-
tients with systemic-onset juvenile idi-
opathic arthritis (SoJIA) and 15 AOSD 
patients with active arthritis, treated 
by anakinra, defi ning the response as 
a resolution of systemic symptoms 
and an improvement of the ACR score. 
The response to anakinra after 3 and 6 
months was rapid and sustained in most 
patients with AOSD and in a signifi cant 
proportion of SoJIA patients: 11 of the 
15 AOSD patients achieved at least a 
50% improvement for all disease mark-
ers (12) The authors suggest that anak-
inra might be more effective in patients 
with highly active systemic disease 
than in those with chronic arthritis. Al-
though AOSD arthritis is known to be 
not progressive or deforming (25), in 
our patients joint involvement and the 
consequent physical inability were the 
most prominent clinical features, while 
systemic symptoms and laboratory ab-
normalities had partially responded to 
conventional treatment. High degree of 
infl ammation was shown by US in the 
affected joints, as demonstrated by the 
presence of signs of synovitis, joint ef-
fusion, hyperperfusion, tenosynovitis. 
Over the last few years, US has become 
an established imaging technique in 
rheumatology because of its ability to 
visualize soft tissue changes and it is 
nowadays considered a fi rst line tool 
for monitoring disease activity and re-
sponse to treatment also with biological 
agents (16).
As far as we know, US has never been 
used to evaluate response to anakinra 
in AOSD: with this tool we could docu-
ment a frank improvement of arthritis 
after the blockade of IL-1 receptor. 
Adopting a sonographic scoring sys-
tem to evaluate the severity of joint 
involvement it was possible to quan-
tify the improvement obtained with 
anakinra. For the same reason, as pre-
viously done (12), we chose to calcu-
late DAS 28 and ACR response. Even 
if larger studies should be performed, 
possibly with a longer follow-up, our 
report, strenghtened by the use of US, 
suggests that anakinra might be useful 
in AOSD also in the presence of severe 
arthritis. This observation is partially in 
contrast to what previously reported by 
Lequerré (12). We could also confi rm 
a steroid sparing activity of anakinra 
as lower levels of corticosteroid were 
required for all our patients after three 
months of treatment. Of note, in one of 
our patient, resistant to MTX clinical 
response persisted after anakinra with-
drawal for adverse effect and clinical 
remission was maintained with meth-
otrexate (previously ineffective) only, 
supporting the role of this drug even 
in remission induction.  Even if an as-
sociation between Turner’s syndrome 
and infl ammatory arthritis have been 
already described (26), the third case 
can be considered a peculiar one in that 
she had also a IgG1 defi ciency which 
was periodically treated with i.v. im-
munoglobulins. Such treatment had no 
impact on AOSD systemic symptoms 
nor on the arthritis which fi nally re-
solved with anakinra. Of note, no side 
effects were recorded in this case. 
In conclusion, this observation sug-
gests that anakinra might be useful for 
AOSD with severe joint involvement 
resistant to conventional treatment.  
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